None listed
Conditions
Interventions
Intervention1: Meningococcal ACWY conjugate vaccine (MenACWY-CRM): One 0.5 mL dose of MenACWY-CRM will be administered by intramuscular (IM)
injection in the deltoid area
Control Intervention1: Not Ap
Sponsors
Novartis Healthcare Pvt Ltd Vaccines Diagnostics
Eligibility
Inclusion criteria
Inclusion criteria: Individuals eligible for enrolment in this study are those: 1. who are of any gender, from the age of 2 to 75 years at the time of visit 1, and to whom the nature of the study has been explained and: • the parent/legal representative has provided written informed consent (greater than or equal to 2 - less than 18 years of age). • have provided written assent (greater than or equal to 7-less than or equal to 18 years) • have provided written informed consent (greater than or equal to 18 to 75 years of age). 2. who the investigator believes that they or their parents/legal representatives can and will comply with the requirements of the protocol (e.g., completion of the Diary Card, return for follow-up visit). 3. who are in good health as determined by medical history, physical exam, clinical judgment of the investigator 4. who have a negative urine pregnancy test for female subjects of childbearing potential
Exclusion criteria
Exclusion criteria: Individuals not eligible to be enrolled in the study are those: 1. who are unwilling or unable to give written informed assent or consent to participate in the study. 2. who are perceived to be unreliable or unavailable for the duration of the study period. 3. who had a previous or suspected disease caused by N. meningitidis. 4. who had household contact with and/or intimate exposure to an individual with culture-proven N. meningitidis infection within 60 days prior to enrolment. 5. who have previously been immunized with a meningococcal vaccine. 6. who have received any investigational or non-registered product (drug or vaccine)within 28 days prior to enrolment or who expect to receive an investigational drug or vaccine prior to the completion of the study. 7. who have received any vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the study vaccines. (Exception: Influenza vaccine may be administered up to 15 days prior to study vaccination and at least 15 days after study vaccination) 8. who have experienced within the 7 days prior to enrolment significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or have experienced fever (defined as body temperature greater than or equal to 38°C) within 3 days prior to enrolment. 9. who have any serious acute, chronic or progressive disease (e.g., any history of neoplasm, cancer, diabetes, cardiac disease, autoimmune disease, HIV infection or AIDS, or blood dyscrasias, with signs of cardiac or renal failure or severe malnutrition). who have epilepsy or any progressive neurological disease. 11. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components. 12. who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example): • receipt of immunosuppressive therapy within 28 days prior to enrolment (any systemic corticosteroid administered for more than 5 days, or in a daily dose greater than 1 mg/kg/day prednisone or equivalent during any of 28 days prior to enrolment, or cancer chemotherapy) • receipt of immunostimulants • receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrolment and for the full length of the study 13. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. 14. who have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the immunogenicity of a single injection of MenACWY-CRM vaccine as measured by the percentage of subjects with hSBA seroresponse, directed against N. meningitidis serogroups A, C, W and Y.Timepoint: at day 29 postvaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the immunogenicity of a single injection of MenACWY-CRM vaccine as measured by hSBA geometric mean titers (GMTs) and by the percentage of subjects with hSBA titer greater than or equal to 1:8, directed against N. meningitidis serogroups A, C, W and Y.Timepoint: at day 29 postvaccination;To assess the safety profile following MenACWY-CRM vaccination in terms of percentage and number of subjects with: â?¢Local and systemic reactions reported from day 1 (day of vaccination) through day 7 post vaccination. â?¢All other adverse events (AEs) reported from day 1 through day 7 postvaccination. â?¢Serious Adverse Events (SAEs) and Medically attended AEs from day 1 through day 29 Timepoint: throught out the study | — |
Countries
India
Contacts
Public ContactDr Rekha J
Novartis Healthcare Pvt Ltd
Outcome results
None listed